BCLSI
KYMR icon

Bain Capital Life Sciences Investors’s Kymera Therapeutics KYMR Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-479,605
Closed -$23.3M – 34
2021
Q2 		$23.3M Hold
479,605
– – 1.52% 16
2021
Q1 		$18.6M Hold
479,605
– – 1.06% 18
2020
Q4 		$29.7M Sell
479,605
-250,001
-34% -$12.2M 1.87% 14
2020
Q3 		$23.6M Buy
+729,606
New +$22.3M 2.2% 11

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bain Capital Life Sciences Investors's KYMR Position: Q3 2021 in Review

Bain Capital Life Sciences Investors sold out of Kymera Therapeutics (KYMR) in Q3 2021, closing a stake of 479,605 shares — an estimated $23.3M sold.

Bain Capital Life Sciences Investors first reported a position in KYMR in Q3 2020 and held it in 4 quarters. The position peaked at $29.7M in Q4 2020. 115 funds tracked by Wall St. Rank hold KYMR as of Q3 2021.

  • Bain Capital Life Sciences Investors reported no remaining Kymera Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 479,605 Kymera Therapeutics shares in Q3 2021, an estimated $23.3M.
  • Bain Capital Life Sciences Investors first reported a position in Kymera Therapeutics in Q3 2020 and held it in 4 quarters.
  • Bain Capital Life Sciences Investors's Kymera Therapeutics position peaked at $29.7M in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2021.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2021, filed 15 Nov 2021.